Keen to stay out front in cell therapy, Gilead's Kite builds its own viral vector manufacturing operations
Days after wooing Christi Shaw to the helm at Kite, Gilead is once again touting just how serious it is about growing its pioneering CAR-T and follow-up cell therapy business. The subsidiary is building a new facility dedicated to viral vector manufacturing within a biologics site at Oceanside, California.
Right now, Kite gets it viral vectors — critical starting material for editing the T cells to activate cancer-killing capabilities — from contract manufacturers, said Tim Moore, EVP of technical operations. But amid a cell therapy boom, the limits that place on commercial supply and development is becoming more apparent.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.